v3.22.2.2

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Mar. 31, 2022
Current assets:
Cash and cash equivalents	$ 49,865	$ 63,729
Restricted cash	1,184	1,184
Prepaid expenses and other current assets	2,335	5,214
Income tax receivable	355	1,609
Total current assets	53,739	71,736
Operating lease right-of-use assets	7	2,444
Property and equipment, net	0	900
Total assets	53,746	75,080
Current liabilities:
Accounts payable	1,963	3,984
Accrued expenses	2,867	8,232
Current portion of operating lease liabilities	4	786
Total current liabilities	4,834	13,002
Operating lease liabilities, net of current portion	0	1,730
Total liabilities	4,834	14,732
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock, par value $0.00001 per share, 1,000,000,000 shares authorized, 73,975,196 and 73,739,378 issued and outstanding at September 30, 2022 and March 31, 2022, respectively	1	1
Additional paid-in capital	923,022	922,966
Accumulated deficit	(874,442)	(862,956)
Accumulated other comprehensive income	331	337
Total stockholders’ equity	48,912	60,348
Total liabilities and stockholders’ equity	$ 53,746	$ 75,080

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Sio Gene Therapies Inc. 10-Q